1 |
VERDOUX H, QUILES C, DE LEON J. Optimizing co-prescription of clozapine and antiseizure medications: a systematic review and expert recommendations for clinical practice[J]. Expert Opin Drug Metab Toxicol, 2024, 20(5): 347-358.
|
2 |
VERDOUX H, QUILES C, DE LEON J. Risks and benefits of clozapine and lithium co-prescribing: a systematic review and expert recommendations[J]. Schizophr Res, 2024, 268: 233-242.
|
3 |
AUGUSTIN M, SCHORETSANITIS G, PFEIFER P, et al. Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations[J]. Schizophr Res, 2019, 210: 143-148.
|
4 |
RAFIZADEH R, SOOCH A, RISI A, et al. Impact of patient-specific factors on clozapine metabolism in individuals with treatment-resistant schizophrenia or schizoaffective disorder[J]. J Psychopharmacol, 2024, 38(6): 526-531.
|
5 |
DAILYMED. Label: clozapine tablet [EB/OL]. [2023-03-30]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=25c0c6d5-f7b0-48e4-e054-00144ff8d46c.
|
6 |
DE LEON J, RAJKUMAR A P, KAITHI A R, et al. Do Asian patients require only half of the clozapine dose prescribed for caucasians? A critical overview[J]. Indian J Psychol Med, 2020, 42(1): 4-10.
|
7 |
HASSAB ERRASOUL A, ALARABI M A. Factors predicting serum clozapine levels in Middle Eastern patients: an observational study[J]. BMC Psychiatry, 2022, 22(1): 269.
|
8 |
CHO C K, KANG P, JANG C G, et al. PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine[J]. Arch Pharm Res, 2024, 47(5): 481-504.
|
9 |
ZHANG Z C, HU M, XUAN D L, et al. Physiologically based pharmacokinetic (PBPK) modeling of BDE-209 following oral exposure in Chinese population[J]. Food Chem Toxicol, 2022, 169: 113416.
|
10 |
LIN W, CHEN Y, UNADKAT J D, et al. Applications, challenges, and outlook for PBPK modeling and simulation: a regulatory, industrial and academic perspective[J]. Pharm Res, 2022, 39(8): 1701-1731.
|
11 |
WILLCOCKS I R, LEGGE S E, NALMPANTI M, et al. Clozapine metabolism is associated with absolute neutrophil count in individuals with treatment-resistant schizophrenia[J]. Front Pharmacol, 2021, 12: 658734.
|
12 |
VAQUERO-BAEZ M, DÍAZ-RUÍZ A, TRISTÁN-LÓPEZ L, et al. Clozapine and desmethylclozapine: correlation with neutrophils and leucocytes counting in Mexican patients with schizophrenia[J]. BMC Psychiatry, 2019, 19(1): 295.
|
13 |
VERDOUX H, QUILES C, DE LEON J. Optimizing antidepressant and clozapine co-prescription in clinical practice: a systematic review and expert recommendations[J]. Schizophr Res, 2024, 268: 243-251.
|
14 |
ZHANG H F, WANG H H, GAO N, et al. Physiological content and intrinsic activities of 10 cytochrome P450 isoforms in human normal liver microsomes[J]. J Pharmacol Exp Ther, 2016, 358(1): 83-93.
|
15 |
SHU Y, CHENG Z N, LIU Z Q, et al. Interindividual variations in levels and activities of cytochrome P-450 in liver microsomes of Chinese subjects[J]. Acta Pharmacol Sin, 2001, 22(3): 283-288.
|
16 |
AN X X, YU Y C, LI G F, et al. Abundance and associated variations of cytochrome P450 drug-metabolizing enzymes in the liver of East Asian adults: a meta-analysis[J]. Eur J Drug Metab Pharmacokinet, 2021, 46(2): 225-233.
|
17 |
ZHU J Y, ZHOU S F, WANG L, et al. Characterization of pediatric rectal absorption, drug disposition, and sedation level for midazolam gel using physiologically based pharmacokinetic/pharmacodynamic modeling[J]. Mol Pharm, 2024, 21(5): 2187-2197.
|
18 |
OWEN J S, FIEDLER-KELLY J. PK/PD建模实践: NONMEM软件入门[M]. 北京: 化学工业出版社, 2020: 69.
|
|
OWEN J S, FIEDLER-KELLY J. Introduction to population pharmacokinetic/pharmcodynamic analysis with nonlinear mixed effects models[M]. Beijing: Chemical Industry Press, 2020: 69.
|
19 |
TASSANEEYAKUL W, KITTIWATTANAGUL K, VANNAPRASAHT S, et al. Steady-state bioequivalence study of clozapine tablet in schizophrenic patients[J]. J Pharm Pharm Sci, 2005, 8(1): 47-53.
|
20 |
ORLANDO R, DE MARTIN S, ANDRIGHETTO L, et al. Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure[J]. Br J Clin Pharmacol, 2010, 69(3): 279-286.
|
21 |
MALLIKAARJUN S, SALAZAR D E, BRAMER S L. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers[J]. J Clin Pharmacol, 2004, 44(2): 179-187.
|
22 |
FUKASAWA T, YASUI-FURUKORI N, SUZUKI A, et al. Effects of caffeine on the kinetics of fluvoxamine and its major metabolite in plasma after a single oral dose of the drug[J]. Ther Drug Monit, 2006, 28(3): 308-311.
|
23 |
LU M L, LANE H Y, CHEN K P, et al. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients[J]. J Clin Psychiatry, 2000, 61(8): 594-599.
|
24 |
KARJALAINEN M J, NEUVONEN P J, BACKMAN J T. In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions[J]. Basic Clin Pharmacol Toxicol, 2008, 103(2): 157-165.
|
25 |
YAO C, KUNZE K L, KHARASCH E D, et al. Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2[J]. Clin Pharmacol Ther, 2001, 70(5): 415-424.
|
26 |
OLESEN O V, LINNET K. Fluvoxamine-clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism[J]. J Clin Psychopharmacol, 2000, 20(1): 35-42.
|
27 |
KIKUCHI R, CHOTHE P P, CHU X Y, et al. Utilization of OATP1B biomarker coproporphyrin-I to guide drug-drug interaction risk assessment: evaluation by the pharmaceutical industry[J]. Clin Pharmacol Ther, 2023, 114(6): 1170-1183.
|
28 |
SCHORETSANITIS G, KANE J M, CORRELL C U, et al. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American society of clinical psychopharmacology and the therapeutic drug monitoring task force of the arbeitsgemeinschaft für neuropsychopharmakologie und pharmakopsychiatrie[J]. J Clin Psychiatry, 2020, 81(3): 19cs13169.
|
29 |
BEREL C, MOSSÉ U, WILS J, et al. Interest of fluvoxamine as an add-on to clozapine in children with severe psychiatric disorder according to CYP polymorphisms: experience from a case series[J]. Front Psychiatry, 2021, 12: 669446.
|
30 |
XU J J, XIAO C F, PAN Y L, et al. Utilizing plasma drug levels and genetic testing to achieve optimal treatment response in a patient with treatment-resistant schizoaffective disorder[J]. Bipolar Disord, 2024, 26(1): 95-97.
|
31 |
BELLON A, NGUYEN K. Selective serotonin reuptake inhibitors and risk reduction for cardiovascular disease in patients with schizophrenia: a controversial but promising approach[J]. World J Psychiatry, 2021, 11(7): 316-324.
|
32 |
DE LEON J, RUAN C J, SCHORETSANITIS G, et al. A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology[J]. Psychother Psychosom, 2020, 89(4): 200-214.
|
33 |
DE LEON J, SCHORETSANITIS G, KANE J M, et al. Using therapeutic drug monitoring to personalize clozapine dosing in Asians[J]. Asia Pac Psychiatry, 2020, 12(2): e12384.
|
34 |
ROWLAND YEO K, GIL BERGLUND E, CHEN Y. Dose optimization informed by PBPK modeling: state-of-the art and future[J]. Clin Pharmacol Ther, 2024, 116(3): 563-576.
|
35 |
GILL J, MOULLET M, MARTINSSON A, et al. Comparing the applications of machine learning, PBPK, and population pharmacokinetic models in pharmacokinetic drug-drug interaction prediction[J]. CPT Pharmacometrics Syst Pharmacol, 2022, 11(12): 1560-1568.
|